Last reviewed · How we verify
PF-07260437 (pf-07260437)
Mechanism of action unknown; experimental oncology compound discontinued during Phase 1 development.
PF-07260437 is an experimental oncology compound developed by Pfizer that was discontinued during Phase 1 clinical development. The drug was being investigated as a potential treatment for advanced or metastatic solid tumors, including ovarian, endometrial, and breast neoplasms. Limited public information is available regarding its specific mechanism of action, molecular target, or pharmacological class. The compound failed to progress beyond early-stage clinical evaluation, suggesting either safety concerns, lack of efficacy signals, or strategic portfolio decisions by Pfizer. No approved indications, regulatory approvals, or commercial revenue data exist for this agent. The discontinuation during Phase 1 indicates the compound did not meet development criteria for advancement to Phase 2 studies.
At a glance
| Generic name | pf-07260437 |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Unknown oncology compound |
| Target | Unknown |
| Modality | Monoclonal antibody |
| Therapeutic area | Oncology |
| Phase | discontinued |
Mechanism of action
PF-07260437 was an experimental compound in Pfizer's oncology pipeline with a molecular weight of 508.49 Da, classified as a non-oral agent based on available ChEMBL data. The specific molecular target, binding mechanism, and pharmacological pathway remain undisclosed in publicly available literature. The compound was evaluated in a Phase 1 trial for advanced or metastatic solid tumors, but development was terminated before sufficient clinical data could establish its mechanism of action or therapeutic potential. Without published clinical results or mechanistic studies, the precise biological activity and target engagement cannot be determined.
Approved indications
Pipeline indications
- Advanced or metastatic solid tumors (including ovarian, endometrial, and breast neoplasms) — Phase 1
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-07260437 CI brief — competitive landscape report
- PF-07260437 updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI